Sensei Biotherapeutics is an immuno-oncology company that focuses on overturning the body’s tolerance of cancer cells and directing its defenses against them. Sensei employs two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. The company is also using its platforms to develop preclinical programs targeting multiple solid tumor indications. Sensei is headquartered in Boston, MA, with an office in Rockville, MD.
52 Week High
52 Week Low
Sep 25, 2022 3:03 AM EDT
Data Provided by Refinitiv. Minimum 15 minutes delayed.